ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that
stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor
blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients
Phase:
Phase 4
Details
Lead Sponsor:
Medical University Innsbruck
Collaborators:
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Ludwig-Maximilians - University of Munich